Orlando Health

410 Medical is a healthcare technology company based in Durham, North Carolina, founded in 2013. The company has developed an innovative rapid infuser device designed to facilitate the swift delivery of fluids to critically ill patients in need of volume resuscitation. This device enhances the speed and efficiency of fluid administration, significantly improving care for patients suffering from life-threatening conditions such as sepsis and shock. By enabling a single healthcare provider to quickly set up and deliver vital fluids, the solution minimizes provider fatigue and allows for simultaneous attention to other patient care needs. It is particularly beneficial in pre-hospital settings and emergency departments, where rapid response is essential and resources may be limited.

Founded in 2014 by Dr. Brian Fengler, EvidenceCare develops clinical decision support systems that integrate into clinicians' electronic health record workflows. Its platform delivers customized, evidence-based guidance to improve care quality and safety, reduce liability, increase operational efficiency, and optimize compliance with government-mandated quality programs.

Francis Medical, Inc., established in 2018 and based in Maple Grove, Minnesota, specializes in the development of innovative medical devices utilizing water vapor technology to treat various urological cancers. The company focuses on prostate, kidney, and bladder cancers, aiming to provide minimally invasive treatments that can potentially reduce life-altering side effects common with traditional methods. Their approach involves using the thermal energy stored in sterile water vapor to ablate cancerous tissue via a simple transurethral procedure.

G.I. Windows, Inc. is a clinical-stage company based in West Bridgewater, Massachusetts, founded in 2012. The company specializes in manufacturing medical devices utilizing advanced surgical anastomotic technology aimed at treating obesity and type 2 diabetes. G.I. Windows is focused on developing innovative solutions that enable less invasive surgical procedures, thereby creating a new category in healthcare. Its technology is designed to enhance the efficiency of diagnostic and interventional procedures, ultimately improving patient outcomes while reducing overall healthcare costs.

Brookwood Baptist Health operates a comprehensive healthcare network in Birmingham, Alabama, comprising five acute care hospitals, a primary care network, and diagnostic/surgical centers. They offer a wide range of services, including emergency care, telehealth, and Medicaid resources, tailoring treatments to individual patient needs. The company aims to build trust and foster relationships within its communities by providing personalized care and leveraging its extensive network of resources and expertise.

Endogenex develops a novel endoscopic procedure using pulsed electric fields to regenerate the duodenal mucosa, aiming to improve glycemic control in patients with Type 2 Diabetes.

Arrivo BioVentures is a biopharmaceutical company based in Morrisville, North Carolina, founded in 2015. It develops biologics and small molecule therapies, including reformulated drugs and new chemical entities, to address patient needs. The company focuses on guiding drug candidates through development with strong regulatory strategies, coordinating early and frequent with the FDA and other authorities to expedite approval and minimize surprises. Its work includes designing efficient clinical programs and identifying regulatory pathways to shorten time to market, with the aim of improving patient outcomes.

410 Medical is a healthcare technology company based in Durham, North Carolina, founded in 2013. The company has developed an innovative rapid infuser device designed to facilitate the swift delivery of fluids to critically ill patients in need of volume resuscitation. This device enhances the speed and efficiency of fluid administration, significantly improving care for patients suffering from life-threatening conditions such as sepsis and shock. By enabling a single healthcare provider to quickly set up and deliver vital fluids, the solution minimizes provider fatigue and allows for simultaneous attention to other patient care needs. It is particularly beneficial in pre-hospital settings and emergency departments, where rapid response is essential and resources may be limited.

Sensydia develops non-invasive cardiac assessment technology, including the Sensydia Cardiac Performance System (CPS), a portable, point-of-care platform that provides real-time hemodynamic readings such as ejection fraction, cardiac output, and pulmonary artery pressure. The system uses AI/machine learning, disposable sensors and cloud connectivity to deliver rapid, non-invasive measurements in hospitals, clinics, offices, and at home, aiding in detection and management of heart failure, sepsis, and pulmonary hypertension, and aiming to reduce the need for invasive procedures. The company is headquartered in Los Angeles, California.

410 Medical is a healthcare technology company based in Durham, North Carolina, founded in 2013. The company has developed an innovative rapid infuser device designed to facilitate the swift delivery of fluids to critically ill patients in need of volume resuscitation. This device enhances the speed and efficiency of fluid administration, significantly improving care for patients suffering from life-threatening conditions such as sepsis and shock. By enabling a single healthcare provider to quickly set up and deliver vital fluids, the solution minimizes provider fatigue and allows for simultaneous attention to other patient care needs. It is particularly beneficial in pre-hospital settings and emergency departments, where rapid response is essential and resources may be limited.

Vergent Bioscience, Inc. is a company focused on improving cancer surgery outcomes through the development of molecularly-targeted imaging probes. Founded in 2013 and based in Minneapolis, Minnesota, Vergent manufactures a tumor-targeted fluorescent probe, known as VGT-309, which binds to enzymes overexpressed in various cancerous tissues. Upon injection prior to surgery, this probe activates a bright fluorescing dye that illuminates cancerous cells, allowing surgeons to differentiate between malignant and normal tissue with enhanced clarity. By providing a clear visual guide during surgical procedures, Vergent's technology aims to facilitate the complete removal of tumors and reduce the likelihood of residual cancer, thereby addressing a critical need in the surgical oncology field. The company's innovative approach is applicable to multiple cancer types, including lung, breast, ovarian, colorectal, and brain cancers, and is designed to support advanced visualization in various surgical techniques, including open, laparoscopic, and robotic surgeries.

Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.

Florida Heart & Vascular Center offers services that are far-reaching in breadth and scope and a team of consultative.

BioStable Science & Engineering, Inc. is a cardiovascular device company based in Austin, Texas, that specializes in developing valve repair technologies as alternatives to valve replacement for patients with aortic valve disease. The company offers a range of HAART aortic valve repair technologies, including the HAART 300 aortic annuloplasty device, designed to reduce annular dilatation and restore three-dimensional annular geometry, and the HAART 200 device tailored for bicuspid aortic valve repair. Additionally, BioStable's aortic root restoration system aims to enhance surgical outcomes for patients with aortic insufficiency or aortic root aneurysm. Founded in 2008, BioStable leverages its expertise in product development, regulatory affairs, and clinical validation to minimize time to market for its innovative medical devices, ultimately improving patient care in the cardiovascular field.

Phynd Technologies Inc. is a healthcare technology company based in Dallas, Texas, founded in 2012. It offers a Software-as-a-Service data management platform designed to simplify the management of healthcare provider data for organizations across the United States. The platform, known as Unified Provider Management (UPM), serves as a central hub for managing critical provider information, including billing addresses, communication preferences, licensing details, and exclusionary lists. Additionally, the platform includes tools for provider enrollment, management, outreach, and search, ensuring that healthcare systems can efficiently maintain and utilize provider data across electronic health records, marketing, and claims systems. Phynd Technologies has gained traction in the healthcare industry, with over 350 hospitals and more than 20,000 locations utilizing its solutions to enhance financial outcomes and clinical results while minimizing compliance risks. The company also offers verification services to further support its clients.

Gauss Surgical, Inc. is a medical technology company that specializes in real-time blood monitoring solutions to enhance patient outcomes in surgical and obstetric settings. Founded in 2011 and headquartered in Los Altos, California, Gauss Surgical develops the Triton system, which includes various models suited for different medical needs. Triton assists healthcare professionals in monitoring and estimating blood loss during procedures, allowing for timely intervention in cases of hemorrhage. The system offers objective metrics for blood loss, thereby facilitating better clinical decision-making regarding transfusions. Serving the healthcare sector primarily in the United States, Gauss Surgical's products are designed to integrate seamlessly into existing medical practices, using sophisticated algorithms and HIPAA-compliant technology to deliver accurate monitoring in real time.

MRI